Cognition Therapeutics, Inc. · NASDAQ:CGTX
Cognition Therapeutics — Alzheimer's Association International Conference (AAIC) 2025
13 slides from Cognition Therapeutics's conference presentation, Jul 27, 2025
Slide 1: Phase 2 Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
Phase 2 Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies Alzheimer’s Association International Conference (AAIC) 2025 Toronto, Ontario, Canada 27 July 2025 James E. Galvin, MD, MPH Director of the Comprehensive Center for Brain Health University of Miami Miller School of Medicine Direct
Slide 2: Disclosures
Disclosures Presenter Disclosures: • Grants from the National Institutes of Health • Consultant for Alpha Cognition, Biogen, Bristol Meyers Squibb, DiagnaMed, Eisai, Eli Lilly, GE Healthcare, Genentech, Lundbeck, Roche, and Thema Medical • Chief Scientific Officer for Cognivue, Inc • Clinical trial
Slide 3: Zervimesine – CT1812
Zervimesine – CT1812 Lead product candidate in development for Dementia with Lewy bodies and Alzheimer’s Dz • BBB-penetrant small molecule oligomer antagonist Zervimesine that displaces BOTH Aβ and α-synuclein oligomers2 PrPc lilrb2 TMEM97 • Distinct MoA: ligand of TMEM97 (sigma-2) receptor PGRMC1 •
Slide 4: SHIMMER Study Designed to Assess Multifactorial Burden
SHIMMER Study Designed to Assess Multifactorial Burden Conducted in Collaboration with LBDA Centers of Excellence, Academic Centers and Industry Partially funded by NIA (R01AG071643) Treatment Period Assessments Study Objectives Disposition 6 months 130 participants randomized from Safety/tolerabili
Slide 5: Patient Characteristics Consistent with Typical DLB Population
Patient Characteristics Consistent with Typical DLB Population Well balanced between treatment and placebo arms 100mg CT1812 300mg CT1812 Placebo Total (n=44) (n=44) (n=42) (n=130) Age – years* 72.6 (7.82) 72.1 (5.90) 73.7 (6.25) 72.8 (6.69) Gender: % Male 79.5 86.4 78.6 81.5 Race: % White 95.5 8
Slide 6: CT1812 Showed 86% Impact on Neuropsychiatric Measures
CT1812 Showed 86% Impact on Neuropsychiatric Measures NPI captures a variety of patient disturbances, including hallucinations, anxiety, and delusions NPI-12 NPI Favors Treatment with CT1812 LS Mean (SE) Difference from Placebo (95% CI) 6 NPI: Neuropsychiatric inventory
Slide 7: Percent Slowing at Day 182 for Exploratory Efficacy Endpoints of Interest
Percent Slowing at Day 182 for Exploratory Efficacy Endpoints of Interest Pooled CT1812 100mg +300 mg vs. Placebo ITT Population 7 Note: The 95% CI for ESS is (-1050, 400) which is too wide to present in this plot alongside the other efficacy endpoints.
Slide 8: Subgroup / Sensitivity Analysis - ADL
Subgroup / Sensitivity Analysis - ADL Favors Zervimesine (n) CT1812 Pbo 73 33 Male: Sex 15 9 Female: 38 23 Low 18-24 MMSE at baseline 49 19 High 25-27 46 16 Below 74 Age 42 26 74 or older 23 15 C2N positive Amyloid positivity 44 18 C2N negative 42 19 Parkinsonian features UPDRS <26 45 23 UPDRS ≥26 7
Slide 9: Biomarkers
Biomarkers No significant treatment differences were observed • Change from baseline levels in plasma were assessed for known markers of Biomarkers: neuroinflammation and disease biology (right) • Reduction in NfL (p>0.10) observed with CT1812 treatment similar to COG0201 in mild-to-moderate AD ❖ Aβ
Slide 10: COG1201 (SHIMMER): Safety Summary
CT1812 Placebo Total Subjects with: 100 mg 300 mg (N=42) (N=129) (N=44) (N=43) At least one TEAE 42 (95.5%) 40 (93.0%) 37 (88.1%) 119 (92.2%) At least one TEAE related to treatment 14 (31.8%) 21 (48.8%) 16 (38.1%) 51 (39.5%) At least one TEAE leading to discontinuation of 4 (9.1%) 9 (20.9%) 5 (11.9%
Slide 11: Summary of SHIMMER Safety and Tolerability findings
Summary of SHIMMER Safety and Tolerability findings Favorable safety profile vs placebo, AEs well balanced between arms Total AE frequency was similar There were no deaths related Participants with LFT elevations in CT1812 and placebo to study drug > 3x ULN • 100mg CT1812 – 3 • 300mg CT1812 –
Slide 12: Strong Early Data Supporting CT1812 for DLB
Strong Early Data Supporting CT1812 for DLB Safety and efficacy to be confirmed in phase 3 trials • SHIMMER suggests CT1812 can slow progression in DLB • Evidence across multiple endpoints • Safe and well tolerated* Behavior Cognition Function Movement • Results support advancement of CT1812 into la
Slide 13: Acknowledgements
Acknowledgements Cognition Therapeutics is grateful to everyone involved in the COG1201 SHIMMER Trial Most importantly – each study participant and their care partners Colleagues at University of Miami Our collaborators at the Lewy Body Dementia Association and their Centers of Excellence Site inves
Cognition Therapeutics — Alzheimer's Association International Conference (AAIC) 2025 on 6ix